Veeda Group Transitions to Veeda Lifesciences with a New Brand Identity

Veeda Group Rebrands as Veeda Lifesciences

In a significant step forward, Veeda Group has rebranded itself as Veeda Lifesciences, complete with a fresh logo and modern brand identity. This change marks a pivotal evolution from a Contract Research Organization (CRO) focused primarily on generics to a more comprehensive drug development services entity capable of handling various modalities, including both generic and innovative drug offerings.

The new identity embodies the integration of Veeda Clinical Research, Health Data Specialists, and Bioneeds India, representing a unified approach to the drug development lifecycle. This transformation emphasizes the transition from being generics-centric to focusing on innovative solutions that span from initial discovery and preclinical studies to late-phase clinical trials. Furthermore, Veeda Lifesciences is adopting a more integrated CRO-CDMO model, underpinned by cutting-edge AI and real-world data utilization.

Dr. Mahesh Bhalgat, Group CEO and Managing Director of Veeda Lifesciences, expressed enthusiasm about this rebranding. He highlighted that the new name and logo reflect the organization's forward-thinking strategy and commitment to its core values. "Veeda Lifesciences signifies our dedication to driving innovation and excellence in service delivery, striving to meet the growing expectations of our clients globally," he stated, underscoring an aspiration towards enhancing client satisfaction and broadening service offerings.

Founded in 2004 in India, Veeda Lifesciences now extends its operations across five countries and carries out clinical trials in 26 different geographies. The acquisition of Bioneeds in 2021 was a strategic move to enhance its capabilities in preclinical testing services, allowing for a broader spectrum of offerings in the life sciences arena. Presently, Veeda Lifesciences operates under four distinct Strategic Business Units (SBUs): Clinical Trials, Healthy Volunteer Services, Biopharma Services, and Preclinical Non-Clinical Testing Services.

Each SBU is structured to address specific aspects of the drug development process. The Clinical Trials unit, for instance, encompasses operations in Europe and patient-centric studies in India. The Healthy Volunteer Services unit operates in Gujarat, India, providing clinical bioanalysis services for small molecules. Meanwhile, the Biopharma Services division located in Bengaluru focuses on characterizing both analytical and functional attributes of biologics, while the Preclinical Testing Services based in Karnataka centers on discovery research in chemistry and biology.

Veeda Lifesciences is committed to delivering a full suite of services throughout all phases of drug development, supporting biotech and pharmaceutical enterprises in accelerating their pipelines through advanced data capabilities offered via an AI platform. Emphasizing quality and scientific rigor, the organization consistently invests in technology and human resources to assist clients in bringing innovative therapies and generics to market for patients worldwide.

As Veeda Lifesciences evolves, it is also preparing for a public issue of equity shares, pending the necessary approvals and market conditions. This move, along with its rebranding, aligns with the organization’s vision to expand further into the global market while enhancing its service portfolio. The company remains dedicated to not only maintaining its quality of service but also ensuring compliance with industry regulations and excellence in scientific output.

In summary, Veeda Lifesciences stands poised to meet the challenges of modern drug development with a renewed identity, emphasizing its commitment to innovation, quality, and comprehensive service across all stages of the drug development continuum.